|
|
||||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
DRUG INTERACTIONS |
From Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (Dr Farid, Mr Ernest, Ms Li, Dr Winters, Dr Small); Lilly Research Center, Ltd, Eli Lilly and Company, Windlesham, UK (Mr Payne); and Daiichi Sankyo Pharma Development, Daiichi Sankyo, Inc, Edison, New Jersey (Dr Salazar). A portion of this work was presented at the 14th North American ISSX Meeting, Rio Grande, Puerto Rico, 2006, and was published in an abstract form in Drug Metab Rev. 2006;38(suppl 2):121.
Prasugrel, a thienopyridine prodrug, is hydrolyzed in vivo by esterases to a thiolactone followed by a single cytochrome P450 (CYP)–dependent step to an active metabolite that is a potent inhibitor of adenosine diphosphate–induced platelet aggregation. This open-label, multiple-dose, 2-period, fixed-sequence study assessed CYP2B6 inhibition by prasugrel using bupropion as a probe substrate, where its active metabolite, hydroxybupropion, is almost exclusively formed by CYP2B6. Thirty healthy subjects received a single 150-mg oral dose of sustained-release bupropion. After a 7-day washout, a 60-mg prasugrel loading dose, followed by a 10-mg daily maintenance dose for 10 days, was administered. Bupropion (150 mg) was given with prasugrel on day 7 of this phase. Prasugrel weakly inhibited CYP2B6 activity as it increased bupropion Cmax and AUC0-
by 14% and 18%, respectively, and decreased hydroxybupropion Cmax and AUC0-
by 32% and 23%. These results are consistent with patients receiving prasugrel not requiring dose adjustments when treated with drugs primarily metabolized by CYP2B6.
Key Words: Bupropion CYP2B6 inhibition hydroxybupropion prasugrel thienopyridines drug interactions
Address for reprints: Nagy A. Farid, PhD, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285; e-mail: nafarid{at}lilly.com.
This article has been cited by other articles:
![]() |
E. T. Williams, K. O. Jones, G. D. Ponsler, S. M. Lowery, E. J. Perkins, S. A. Wrighton, K. J. Ruterbories, M. Kazui, and N. A. Farid The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2 Drug Metab. Dispos., July 1, 2008; 36(7): 1227 - 1232. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |